4568 Stock Overview
Manufactures, markets, and sells pharmaceutical products worldwide.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 3/6 |
| Past Performance | 5/6 |
| Financial Health | 6/6 |
| Dividends | 3/6 |
Rewards
Risk Analysis
No risks detected for 4568 from our risk checks.
Daiichi Sankyo Company, Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | JP¥5,531.00 |
| 52 Week High | JP¥5,520.00 |
| 52 Week Low | JP¥3,566.00 |
| Beta | 0.26 |
| 1 Month Change | 24.49% |
| 3 Month Change | 13.34% |
| 1 Year Change | 11.27% |
| 3 Year Change | 110.14% |
| 5 Year Change | 197.90% |
| Change since IPO | 616.76% |
Recent News & Updates
Statutory Profit Doesn't Reflect How Good Daiichi Sankyo Company's (TSE:4568) Earnings Are
May 02
Daiichi Sankyo Company, Limited Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year
Apr 27Recent updates
Statutory Profit Doesn't Reflect How Good Daiichi Sankyo Company's (TSE:4568) Earnings Are
May 02Daiichi Sankyo Company, Limited Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year
Apr 27Daiichi Sankyo Company (TSE:4568) Is Paying Out A Larger Dividend Than Last Year
Mar 11Daiichi Sankyo Company (TSE:4568) Will Pay A Larger Dividend Than Last Year At ¥30.00
Feb 26Shareholder Returns
| 4568 | JP Pharmaceuticals | JP Market | |
|---|---|---|---|
| 7D | 2.7% | 1.6% | 0.6% |
| 1Y | 11.3% | 5.3% | 24.2% |
Return vs Industry: 4568 exceeded the JP Pharmaceuticals industry which returned 5.3% over the past year.
Return vs Market: 4568 underperformed the JP Market which returned 24.2% over the past year.
Price Volatility
| 4568 volatility | |
|---|---|
| 4568 Average Weekly Movement | 4.5% |
| Pharmaceuticals Industry Average Movement | 3.8% |
| Market Average Movement | 4.1% |
| 10% most volatile stocks in JP Market | 8.1% |
| 10% least volatile stocks in JP Market | 2.2% |
Stable Share Price: 4568 has not had significant price volatility in the past 3 months.
Volatility Over Time: 4568's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1899 | 17,435 | Sunao Manabe | www.daiichisankyo.com |
Daiichi Sankyo Company, Limited manufactures, markets, and sells pharmaceutical products worldwide. The company offers Enhertu, a HER2 directed antibody drug conjugate; Turalio, a CSF-1R inhibitor; Vanflyta, a FLT3 inhibitor for the treatment of adult patients with relapsed/refractory FLT3-ITD acute myeloid leukemia; ferric carboxymaltose injection for treating anaemia; and Injectafer for the treatment for iron deficiency anaemia. It also provides olmesartan medoxomil antihypertensive agents; NILEMDO, an oral treatment to help in lowering cholesterol; and Nustendi, a fixed-dose combination tablet of bempedoic acid and ezetimibe for reducing cholesterol.
Daiichi Sankyo Company, Limited Fundamentals Summary
| 4568 fundamental statistics | |
|---|---|
| Market cap | JP¥10.51t |
| Earnings (TTM) | JP¥200.73b |
| Revenue (TTM) | JP¥1.60t |
52.8x
P/E Ratio6.6x
P/S RatioIs 4568 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 4568 income statement (TTM) | |
|---|---|
| Revenue | JP¥1.60t |
| Cost of Revenue | JP¥415.32b |
| Gross Profit | JP¥1.19t |
| Other Expenses | JP¥985.64b |
| Earnings | JP¥200.73b |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 104.71 |
| Gross Margin | 74.07% |
| Net Profit Margin | 12.53% |
| Debt/Equity Ratio | 6.0% |
How did 4568 perform over the long term?
See historical performance and comparison